Opinion|Videos|January 13, 2025
Key Considerations for the Evolving Treatment Landscape for Relapsed/Refractory Follicular Lymphoma
Author(s)Juan Pablo Alderuccio, MD
A panelist discusses how various antibody-drug conjugates, including polatuzumab vedotin, pinatuzumab vedotin, and loncastuximab, have been studied in combination with rituximab for relapsed/refractory follicular lymphoma. Recent data from ASH 2024 highlight important patient considerations for these treatment approaches.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Other antibody-drug conjugates have been examined in the relapsed/refractory follicular lymphoma (R/R FL) space in combination with rituximab.
- Polatuzumab vedotin + rituximab and pinatuzumab vedotin + rituximab. In the R/R FL population, how do these agents perform?
- Given the data update from Alderuccio et al. ASH 2024, comment on how loncastuximab + rituximab could play a role in the treatment landscape for R/R FL. What patient considerations are critical to note?
Advertisement
Related to this article
Giredestrant plus everolimus reduced the risk of progression or death by 44% in the ITT population and 62% in ESR1-mutated disease in phase 3 evERA data published in NEJM.
The oral azacitidine/cedazuridine combination was compared with subcutaneous azacitidine in the phase 3 portion of the AZTOUND trial.
Adding zabilugene almadenorepvec to standard gemcitabine/nab-paclitaxel extends survival and response in newly diagnosed metastatic pancreatic cancer, with manageable safety signals.
Late 2026 FDA oncology rulings may reshape care—from CSF-1R and ALK drugs to oral SERDs and BCMA CAR T breakthroughs.
Resubmitted FDA filing advances off-the-shelf EBV-specific T-cell therapy tab-cel for relapsed EBV+ PTLD after transplant, with longer follow-up.
Resection with cesium-131 tile-based radiation therapy prolonged time to surgical bed recurrence vs resection with stereotactic radiation in the phase 3 ROADS trial.
Degevma was approved for skeletal-related events in adults with bone metastases, giant cell tumor of bone, and the treatment of hypercalcemia of malignancy.
FDA fast-tracks plinabulin plus docetaxel for post-immunotherapy non-squamous NSCLC, as DUBLIN-4 phase 3 targets survival gains.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Giredestrant Plus Everolimus Improves PFS in ER+ Advanced Breast Cancer
2
New Drug Application Filed for Savolitinib/Osimertinib in MET+ NSCLC
3
Q4 2026 Oncology Outlook: Key FDA Decisions to Watch
4
Zabilugene Almadenorepvec Plus Chemo Shows Survival Gains in Metastatic PDAC
5